(Q53277140)

English

Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.

scientific article published on 11 February 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21214673

Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21214673

1 reference

based on heuristic

inferred from title

RNA interference

1 reference

based on heuristic

inferred from title

author name string

Iori Sakai

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21214673

Hideaki Miyake

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21214673

Tomoaki Terakawa

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21214673

Masato Fujisawa

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21214673

publication date

11 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21214673

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21214673

102

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21214673

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21214673

769-775

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21214673

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Mechanisms of the development of androgen independence in prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Mechanisms leading to the development of hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

From pathogenesis to prevention of castration resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Interleukin-6 and its receptor: a paradigm for cytokines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Interleukin-6 and its receptor in cancer: implications for translational therapeutics

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Interleukin-6 is an autocrine growth factor in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Androgen receptor signaling: mechanism of interleukin-6 inhibition.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway .

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Interleukin-6: a candidate mediator of human prostate cancer morbidity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Preoperative chemotherapy increases cytokine production after lung cancer surgery

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

NF-kappaB in cancer: from innocent bystander to major culprit

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01854.X

21 January 2018

Identifiers

10.1111/J.1349-7006.2011.01854.X

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21214673

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21214673

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53277140&oldid=1587930255"